Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

CDK11 Loss Induces Cell Cycle Dysfunction and Death of BRAF and NRAS Melanoma Cells.

Ahmed RL, Shaughnessy DP, Knutson TP, Vogel RI, Ahmed K, Kren BT, Trembley JH.

Pharmaceuticals (Basel). 2019 Apr 2;12(2). pii: E50. doi: 10.3390/ph12020050.

2.

Patient satisfaction with patient-provider interactions at time of diagnosis among early stage melanoma survivors - a cross-sectional survey.

Zaffran K, Lazovich D, Boull C, Vogel RI.

J Am Acad Dermatol. 2019 Apr 12. pii: S0190-9622(19)30600-0. doi: 10.1016/j.jaad.2019.04.014. [Epub ahead of print] No abstract available.

PMID:
30986476
3.

The American College of Surgeon's surgical risk calculator's ability to predict disposition in older gynecologic oncology patients undergoing laparotomy.

Shaker S, Rivard C, Nahum R, Vogel RI, Teoh D.

J Geriatr Oncol. 2019 Feb 22. pii: S1879-4068(18)30313-8. doi: 10.1016/j.jgo.2019.02.008. [Epub ahead of print]

PMID:
30803821
4.

Evaluation of graphic messages to promote human papillomavirus vaccination among young adults: A statewide cross-sectional survey.

Teoh D, Shaikh R, Schnaith A, Lou E, McRee AL, Nagler RH, Vogel RI.

Prev Med Rep. 2019 Jan 11;13:256-261. doi: 10.1016/j.pmedr.2019.01.002. eCollection 2019 Mar.

5.

A patient-centered mobile health application to motivate use of genetic counseling among women with ovarian cancer: A pilot randomized controlled trial.

Vogel RI, Niendorf K, Petzel S, Lee H, Teoh D, Blaes AH, Argenta P, Rivard C, Winterhoff B, Lee HY, Geller MA.

Gynecol Oncol. 2019 Apr;153(1):100-107. doi: 10.1016/j.ygyno.2019.01.019. Epub 2019 Feb 1.

PMID:
30718125
6.

Patterns of Immunohistochemistry Utilization in Metastases to the Liver.

Amin K, El-Rayes D, Snover D, Mettler T, Vogel RI, Khalifa MA.

Appl Immunohistochem Mol Morphol. 2018 Sep 5. doi: 10.1097/PAI.0000000000000643. [Epub ahead of print]

PMID:
30192243
7.

Assessment of Circulating Tumor Cells as a Predictive Biomarker of Histology in Women With Suspected Ovarian Cancer.

Lou E, Vogel RI, Teoh D, Hoostal S, Grad A, Gerber M, Monu M, Lukaszewski T, Deshpande J, Linden MA, Geller MA.

Lab Med. 2018 Mar 21;49(2):134-139. doi: 10.1093/labmed/lmx084.

8.

A Qualitative Study of Quality of Life Concerns following a Melanoma Diagnosis.

Vogel RI, Strayer LG, Ahmed RL, Blaes A, Lazovich D.

J Skin Cancer. 2017;2017:2041872. doi: 10.1155/2017/2041872. Epub 2017 May 28.

9.

Assessment of the Intraoperative Consultation Service Rendered by General Pathologists in a Scenario Where a Well-Defined Decision Algorithm Is Followed.

Khalifa MA, Salama S, Vogel RI, Klein ME, Richter J, Pulver T, Mullany SA, Winterhoff B.

Am J Clin Pathol. 2017 Mar 1;147(3):322-326. doi: 10.1093/ajcp/aqw223.

10.

CK2 Molecular Targeting-Tumor Cell-Specific Delivery of RNAi in Various Models of Cancer.

Trembley JH, Kren BT, Abedin MJ, Vogel RI, Cannon CM, Unger GM, Ahmed K.

Pharmaceuticals (Basel). 2017 Feb 21;10(1). pii: E25. doi: 10.3390/ph10010025. Review.

11.

Early elective delivery and vaginal birth after cesarean in rural US maternity hospitals.

Heinrich D, Vogel RI, Kozhimannil KB.

Rural Remote Health. 2016 Oct-Dec;16(4):3956. Epub 2016 Nov 15.

12.

Prognostic factors for survival in advanced appendiceal cancers.

Khan F, Vogel RI, Diep GK, Tuttle TM, Lou E.

Cancer Biomark. 2016;17(4):457-462. doi: 10.3233/CBM-160662.

13.

CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumors.

Ahmed K, Kren BT, Abedin MJ, Vogel RI, Shaughnessy DP, Nacusi L, Korman VL, Li Y, Dehm SM, Zimmerman CL, Niehans GA, Unger GM, Trembley JH.

Oncotarget. 2016 Sep 20;7(38):61789-61805. doi: 10.18632/oncotarget.11442.

14.

Tunneling nanotube formation is stimulated by hypoxia in ovarian cancer cells.

Desir S, Dickson EL, Vogel RI, Thayanithy V, Wong P, Teoh D, Geller MA, Steer CJ, Subramanian S, Lou E.

Oncotarget. 2016 Jul 12;7(28):43150-43161. doi: 10.18632/oncotarget.9504.

15.

Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.

Kren BT, Unger GM, Abedin MJ, Vogel RI, Henzler CM, Ahmed K, Trembley JH.

Breast Cancer Res. 2015;17:19. doi: 10.1186/s13058-015-0524-0. Epub 2015 Feb 11.

16.

Cervical cancer screening with clinic-based Pap test versus home HPV test among Somali immigrant women in Minnesota: a pilot randomized controlled trial.

Sewali B, Okuyemi KS, Askhir A, Belinson J, Vogel RI, Joseph A, Ghebre RG.

Cancer Med. 2015 Apr;4(4):620-31. doi: 10.1002/cam4.429. Epub 2015 Feb 4.

17.

Intercellular communication in malignant pleural mesothelioma: properties of tunneling nanotubes.

Ady JW, Desir S, Thayanithy V, Vogel RI, Moreira AL, Downey RJ, Fong Y, Manova-Todorova K, Moore MA, Lou E.

Front Physiol. 2014 Oct 31;5:400. doi: 10.3389/fphys.2014.00400. eCollection 2014.

18.

Tenfibgen ligand nanoencapsulation delivers bi-functional anti-CK2 RNAi oligomer to key sites for prostate cancer targeting using human xenograft tumors in mice.

Trembley JH, Unger GM, Korman VL, Abedin MJ, Nacusi LP, Vogel RI, Slaton JW, Kren BT, Ahmed K.

PLoS One. 2014 Oct 15;9(10):e109970. doi: 10.1371/journal.pone.0109970. eCollection 2014.

19.

Mechanism and efficacy of sub-50-nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinoma.

Unger GM, Kren BT, Korman VL, Kimbrough TG, Vogel RI, Ondrey FG, Trembley JH, Ahmed K.

Mol Cancer Ther. 2014 Aug;13(8):2018-29. doi: 10.1158/1535-7163.MCT-14-0166. Epub 2014 May 27.

20.

Tenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation.

Trembley JH, Unger GM, Gomez OC, Abedin J, Korman VL, Vogel RI, Niehans G, Kren BT, Ahmed K.

Mol Cell Pharmacol. 2014;6(2):15-25.

Supplemental Content

Loading ...
Support Center